T1	intervention 32 48	N-Acetylcysteine
T2	condition 81 117	Anthracycline-Induced Cardiomyopathy
T3	total-participants 285 288	103
T4	eligibility 381 519	patients first diagnosed with breast cancer or lymphoma, who require chemotherapy, including anthracycline like adriamycine or epirubicine
T5	intervention-participants 566 568	50
T6	control 715 728	control group
T7	control-participants 732 734	53
T8	outcome-Measure 761 814	decrease in left ventricular ejection fraction (LVEF)
T9	outcome 963 978	primary outcome
T10	iv-bin-abs 1042 1043	3
T11	intervention-participants 1044 1046	47
T12	iv-bin-percent 1048 1052	6.4%
T13	cv-bin-abs 1058 1059	1
T14	control-participants 1060 1062	52
T15	cv-bin-percent 1064 1068	1.9%
T16	outcome 1085 1094	mean LVEF
T17	outcome 1262 1278	mean LVEF change
T18	outcome 1371 1415	Left ventricular (LV) end systolic dimension
T19	outcome 1529 1555	LV end diastolic dimension
T21	outcome 1703 1733	Cumulative 12-month event rate
T22	iv-bin-percent 1738 1740	6%
T23	cv-bin-percent 1745 1749	3.8%
T26	iv-cont-mean 1318 1324	-3.64%
T27	cv-cont-mean 1336 1342	-2.78%
T24	iv-cont-mean 1454 1458	3.08
T25	iv-cont-sd 1459 1466	4.56 mm
T28	cv-cont-mean 1484 1488	1.47
T29	cv-cont-sd 1489 1496	1.83 mm
T30	iv-cont-mean 1149 1154	60.8%
T31	cv-cont-mean 1198 1203	61.3%
T20	outcome 1621 1627	Peak E
T32	outcome 1629 1651	A and E/A ratio change
T33	outcome 1656 1671	cardiac enzymes
